Feedback

US researchers confirm effectiveness of low-cost antidepressant in preventing hospitalization from Covid-19

Source : 112 Ukraine

Of the 741 participants in the experiment who took the antidepressant fluvoxamine, only 75 required hospitalization
08:03, 29 October 2021

Open source

U.S. researchers have confirmed the effectiveness of an inexpensive antidepressant in preventing hospitalization from Covid-19, The Lancet reports.

"Recent evidence indicates a potential therapeutic role of fluvoxamine for COVID-19," the statement reads.

The experiment of American scientists with fluvoxamine involved 741 people from 11 clinical centers in Brazil. Patients in the early stages of Covid-19 with a risk factor for severe disease (patients with diabetes, cardiovascular disease, lung disease, obesity, smoking, etc.) were admitted to the study.

It is noted that as a result of the study, of the 741 participants taking the antidepressant fluvoxamine, only 75 required hospitalization. In seven days of the experiment, 40 people recovered from the coronavirus.

Fluvoxamine is a synthetic drug that belongs to the group of selective serotonin reuptake inhibitors. Used for depression of various origins and obsessive-compulsive disorders.

Related: Lockdown in Ukraine: Red cities and new restrictions

Topics:
Система Orphus

If you find an error, highlight the desired text and press Ctrl + Enter, to tell about it

Comments
see more